Average cost of drug per patient per year is $140,000 "and that is declining," firm says in April 2 statement taking issue with estimates made by Rep. Stark (D-Calif.) in introduction to his orphan drug windfall profit tax bill. Genzyme expects that average maintenance therapy with Ceredase will cost under $60,000 per patient annually. Currently, about 800 patients are being treated with the drug, firm says.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth